TWI853014B - 使用2-(2,6-二氧六氫吡啶-3-基)-4-((2-氟-4-((3-嗎啉基氮雜環丁烷-1-基)甲基)苄基)胺基)異吲哚啉-1,3-二酮治療非霍奇金氏淋巴瘤的方法 - Google Patents

使用2-(2,6-二氧六氫吡啶-3-基)-4-((2-氟-4-((3-嗎啉基氮雜環丁烷-1-基)甲基)苄基)胺基)異吲哚啉-1,3-二酮治療非霍奇金氏淋巴瘤的方法 Download PDF

Info

Publication number
TWI853014B
TWI853014B TW109112033A TW109112033A TWI853014B TW I853014 B TWI853014 B TW I853014B TW 109112033 A TW109112033 A TW 109112033A TW 109112033 A TW109112033 A TW 109112033A TW I853014 B TWI853014 B TW I853014B
Authority
TW
Taiwan
Prior art keywords
compound
nhl
rituximab
lymphoma
dlbcl
Prior art date
Application number
TW109112033A
Other languages
English (en)
Chinese (zh)
Other versions
TW202103705A (zh
Inventor
瑪麗亞 薩拉亞 克倫西歐 安東
塔尼亞 J 巴克霍爾茲
吉羅那 安東尼亞 羅培茲
拉瑪 克里斯娜 娜拉
麥可 普德耐
Original Assignee
美商西建公司
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 美商西建公司 filed Critical 美商西建公司
Publication of TW202103705A publication Critical patent/TW202103705A/zh
Application granted granted Critical
Publication of TWI853014B publication Critical patent/TWI853014B/zh

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2887—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against CD20
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Endocrinology (AREA)
  • Dermatology (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
TW109112033A 2019-04-12 2020-04-09 使用2-(2,6-二氧六氫吡啶-3-基)-4-((2-氟-4-((3-嗎啉基氮雜環丁烷-1-基)甲基)苄基)胺基)異吲哚啉-1,3-二酮治療非霍奇金氏淋巴瘤的方法 TWI853014B (zh)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201962833432P 2019-04-12 2019-04-12
US62/833,432 2019-04-12

Publications (2)

Publication Number Publication Date
TW202103705A TW202103705A (zh) 2021-02-01
TWI853014B true TWI853014B (zh) 2024-08-21

Family

ID=70465546

Family Applications (1)

Application Number Title Priority Date Filing Date
TW109112033A TWI853014B (zh) 2019-04-12 2020-04-09 使用2-(2,6-二氧六氫吡啶-3-基)-4-((2-氟-4-((3-嗎啉基氮雜環丁烷-1-基)甲基)苄基)胺基)異吲哚啉-1,3-二酮治療非霍奇金氏淋巴瘤的方法

Country Status (27)

Country Link
US (3) US11390617B2 (cg-RX-API-DMAC7.html)
EP (1) EP3952880B1 (cg-RX-API-DMAC7.html)
JP (1) JP7562557B2 (cg-RX-API-DMAC7.html)
KR (1) KR102944213B1 (cg-RX-API-DMAC7.html)
CN (1) CN114144182B (cg-RX-API-DMAC7.html)
AR (1) AR119715A1 (cg-RX-API-DMAC7.html)
AU (1) AU2020270917B2 (cg-RX-API-DMAC7.html)
BR (1) BR112021020372A2 (cg-RX-API-DMAC7.html)
CA (1) CA3132538A1 (cg-RX-API-DMAC7.html)
CL (1) CL2021002651A1 (cg-RX-API-DMAC7.html)
DK (1) DK3952880T3 (cg-RX-API-DMAC7.html)
ES (1) ES3061998T3 (cg-RX-API-DMAC7.html)
FI (1) FI3952880T3 (cg-RX-API-DMAC7.html)
HR (1) HRP20251668T1 (cg-RX-API-DMAC7.html)
IL (1) IL287145A (cg-RX-API-DMAC7.html)
LT (1) LT3952880T (cg-RX-API-DMAC7.html)
MA (1) MA55608A (cg-RX-API-DMAC7.html)
MX (1) MX428518B (cg-RX-API-DMAC7.html)
PL (1) PL3952880T3 (cg-RX-API-DMAC7.html)
PT (1) PT3952880T (cg-RX-API-DMAC7.html)
RS (1) RS67593B1 (cg-RX-API-DMAC7.html)
SG (1) SG11202111232RA (cg-RX-API-DMAC7.html)
SI (1) SI3952880T1 (cg-RX-API-DMAC7.html)
SM (1) SMT202600013T1 (cg-RX-API-DMAC7.html)
TW (1) TWI853014B (cg-RX-API-DMAC7.html)
WO (1) WO2020210418A1 (cg-RX-API-DMAC7.html)
ZA (1) ZA202107668B (cg-RX-API-DMAC7.html)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN113573719A (zh) 2018-11-08 2021-10-29 朱诺治疗学股份有限公司 治疗和t细胞调节的方法和组合
AU2020369497C1 (en) * 2019-10-21 2026-05-07 Celgene Corporation Methods of treating chronic lymphocytic leukemia using 2-(2,6-dioxopiperidin-3yl)-4-((2-fluoro-4-((3-morpholinoazetidin-1-yl)methyl)benzyl)amino)isoindoline-1. 3-dione
IL292375A (en) 2019-10-21 2022-06-01 Celgene Corp Solid forms include (s)-2-(2,6-dioxopiperidin-3-yl)-4-((2-fluoro-4-((3-morpholinoazetidin-1-yl)metyl)benzyl)amino)isoindoline-1 3- Discussion and salts from them, and preparations that include the same and their use
AU2020372333B2 (en) * 2019-10-21 2026-08-06 Celgene Corporation Methods for treating a hematological cancer and the use of companion biomarkers for 2-(2,6-Dioxopiperidin-3-yl)-4-((2-fluoro-4-((3-morpholinoazetidin-1-yl)methyl)benzyl)amino)isoindoline-1,3-dione
SMT202600194T1 (it) * 2019-10-21 2026-05-12 Celgene Corp Combinazione di composti di 4-amminoisoindolin-1,3-dione sostituiti e di secondi agenti attivi per l'uso nel trattamento di una condizione maligna ematologica
HRP20231487T1 (hr) 2019-10-21 2024-03-01 Celgene Corporation Postupci za liječenje hematoloških malignosti uporabom 2-(2,6-dioksopiperidin-3-il)-4-((2-fluoro-4-((3-morfolinoazetidin-1-il)metil)benzil)amino)izoindolin-1,3-diona
CN114885602A (zh) * 2019-10-21 2022-08-09 新基公司 包含(s)-2-(2,6-二氧代哌啶-3-基)-4-((2-氟-4-((3-吗啉代氮杂环丁烷-1-基)甲基)苄基)氨基)异吲哚啉-1,3-二酮的药物组合物及其使用方法
IL307257A (en) * 2021-03-29 2023-11-01 Juno Therapeutics Inc A combination of car cell therapy and an immunomodulatory compound for the treatment of lymphoma
US20240207281A1 (en) * 2021-04-21 2024-06-27 Celgene Corporation Methods of treating b-cell lymphoma using combination therapy
CN117241802A (zh) * 2021-04-21 2023-12-15 新基公司 使用2-(2,6-二氧代哌啶-3-基)-4-((2-氟-4-((3-吗啉代氮杂环丁烷-1-基)甲基)苄基)氨基)异吲哚啉-1,3-二酮治疗非霍奇金淋巴瘤的方法
AU2022300184A1 (en) 2021-06-21 2023-11-16 Celgene Corporation Processes for the preparation of (s)-2-(2,6-dioxopiperidin-3-yl)-4-((2-fluoro-4-((3-morpholinoazetidin-1-yl) methyl)benzyl) amino)isoindoline-1,3-dione
WO2026099206A1 (en) 2024-11-05 2026-05-15 Celgene Corporation Therapy for the treatment of non-hodgkin lymphoma

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2008033567A1 (en) * 2006-09-15 2008-03-20 Celgene Corporation N-methylaminomethyl isoindole compounds and compositions comprising and methods of using the same
CN105246480A (zh) * 2013-04-02 2016-01-13 细胞基因公司 使用4-氨基-2-(2,6-二氧代-哌啶-3-基)-异吲哚啉-1,3-二酮治疗和控制中枢神经系统癌症的方法和组合物
WO2019209692A1 (en) * 2018-04-23 2019-10-31 Celgene Corporation Substituted 4-aminoisoindoline-1,3-dione compounds and their use for treating lymphoma

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2430669C (en) 2000-11-30 2011-06-14 The Children's Medical Center Corporation Synthesis of 3-amino-thalidomide and its enantiomers
EP3351240B1 (en) 2009-05-19 2019-04-10 Celgene Corporation Formulations of 4-amino-2-(2,6-dioxopiperidine-3-yl)isoindoline-1,3-dione
SG183257A1 (en) * 2010-02-11 2012-09-27 Celgene Corp Arylmethoxy isoindoline derivatives and compositions comprising and methods of using the same
WO2012177678A2 (en) * 2011-06-22 2012-12-27 Celgene Corporation Isotopologues of pomalidomide
UA116544C2 (uk) * 2012-08-09 2018-04-10 Селджин Корпорейшн Спосіб лікування раку з використанням 3-(4-((4-(морфолінометил)бензил)оксі)-1-оксоізоіндолін-2-іл)піперидин-2,6-діону
US20150297579A1 (en) 2012-11-05 2015-10-22 Celgene Corporation Treatment of cancer with pomalidomide in a renally impaired subject
NZ731789A (en) * 2014-10-30 2019-04-26 Kangpu Biopharmaceuticals Ltd Isoindoline derivative, intermediate, preparation method, pharmaceutical composition and use thereof
JP7258009B2 (ja) * 2017-07-10 2023-04-14 セルジーン コーポレイション 抗増殖化合物及びその使用方法

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2008033567A1 (en) * 2006-09-15 2008-03-20 Celgene Corporation N-methylaminomethyl isoindole compounds and compositions comprising and methods of using the same
CN105246480A (zh) * 2013-04-02 2016-01-13 细胞基因公司 使用4-氨基-2-(2,6-二氧代-哌啶-3-基)-异吲哚啉-1,3-二酮治疗和控制中枢神经系统癌症的方法和组合物
WO2019209692A1 (en) * 2018-04-23 2019-10-31 Celgene Corporation Substituted 4-aminoisoindoline-1,3-dione compounds and their use for treating lymphoma

Also Published As

Publication number Publication date
RS67593B1 (sr) 2026-01-30
EP3952880A1 (en) 2022-02-16
IL287145A (en) 2021-12-01
SMT202600013T1 (it) 2026-03-09
US11390617B2 (en) 2022-07-19
PL3952880T3 (pl) 2026-05-18
MX428518B (es) 2025-11-13
BR112021020372A2 (pt) 2021-12-07
JP2022527398A (ja) 2022-06-01
US20200325129A1 (en) 2020-10-15
AU2020270917A1 (en) 2021-11-04
DK3952880T3 (da) 2026-01-26
WO2020210418A1 (en) 2020-10-15
EP3952880B1 (en) 2025-12-10
US20240400548A1 (en) 2024-12-05
ES3061998T3 (en) 2026-04-08
HRP20251668T1 (hr) 2026-02-27
US20220324855A1 (en) 2022-10-13
KR20210151895A (ko) 2021-12-14
ZA202107668B (en) 2025-01-29
MX2021012507A (es) 2022-01-24
LT3952880T (lt) 2026-01-26
MA55608A (fr) 2022-02-16
US12103923B2 (en) 2024-10-01
SI3952880T1 (sl) 2026-02-27
JP7562557B2 (ja) 2024-10-07
FI3952880T3 (fi) 2026-02-05
AR119715A1 (es) 2022-01-05
CA3132538A1 (en) 2020-10-15
AU2020270917B2 (en) 2025-08-28
TW202103705A (zh) 2021-02-01
KR102944213B1 (ko) 2026-03-26
CN114144182A (zh) 2022-03-04
CL2021002651A1 (es) 2022-04-29
SG11202111232RA (en) 2021-11-29
PT3952880T (pt) 2026-02-17
CN114144182B (zh) 2024-05-24

Similar Documents

Publication Publication Date Title
US12103923B2 (en) Methods of treating non-hodgkin lymphoma using 2-(2,6-dioxopiperidin-3-yl)-4-((2-fluoro-4-((3-morpholinoazetidin-1-yl)methyl)benzyl)amino)isoindoline-1,3-dione
US11628172B2 (en) Methods of treating chronic lymphocytic leukemia using 2-(2,6-dioxopiperidin-3-yl)-4-((2-fluoro-4-((3-morpholinoazetidin-1-yl)methyl)benzyl)amino)isoindoline-1,3-dione
US20100226917A1 (en) Methods for the treatment of hematologic malignancies
EA047955B1 (ru) Способы лечения неходжкинской лимфомы с использованием 2-(2,6-диоксопиперидин-3-ил)-4-((2-фтор-4-((3-морфолиноазетидин-1-ил)метил)бензил)амино)изоиндолин-1,3-диона
US20240207281A1 (en) Methods of treating b-cell lymphoma using combination therapy
US20220362255A1 (en) Methods of treating non-hodgkin lymphoma using 2-(2,6-dioxopiperidin-3-yl)-4-((2-fluoro-4-((3-morpholinoazetidin-1-yl)methyl)benzyl)amino)isoindoline-1,3-dione
EA046110B1 (ru) Способы лечения хронического лимфоцитарного лейкоза с применением 2-(2,6-диоксопиперидин-3-ил)-4-((2-фтор-4-((3-морфолиноазетидин-1-ил)метил)бензил)амино)изоиндолин-1,3-диона